{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=blood+biomarker&page=10", "query": { "intervention": "blood biomarker", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 1740, "total_pages": 174, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=blood+biomarker&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=blood+biomarker&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T12:11:36.224Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03220009", "title": "Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Carcinoma", "Esophageal Carcinoma", "Mucosal Melanoma", "Mucosal Melanoma of the Head and Neck", "Oral Cavity Mucosal Melanoma", "Recurrent Melanoma", "Stage II Vulvar Cancer AJCC v7", "Stage III Vulvar Cancer AJCC v7", "Stage IIIA Vulvar Cancer AJCC v7", "Stage IIIB Vulvar Cancer AJCC v7", "Stage IIIC Vulvar Cancer AJCC v7", "Stage IV Oral Cavity Cancer AJCC v6 and v7", "Stage IV Vulvar Cancer AJCC v7", "Stage IVA Oral Cavity Cancer AJCC v6 and v7", "Stage IVB Oral Cavity Cancer AJCC v6 and v7", "Stage IVC Oral Cavity Cancer AJCC v6 and v7", "Vaginal Carcinoma" ], "interventions": [ { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-11-03", "completion_date": "2021-07-01", "has_results": false, "last_update_posted_date": "2018-10-03", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220009" }, { "nct_id": "NCT02003209", "title": "Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2-Positive Breast Carcinoma", "Hormone Receptor-Positive Breast Carcinoma", "Stage IB Breast Cancer AJCC v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Aromatase Inhibition Therapy", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Whole Breast Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 315, "start_date": "2014-02-18", "completion_date": "2025-06-30", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 731, "location_summary": "Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Antioch", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02003209" }, { "nct_id": "NCT04224493", "title": "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Follicular Lymphoma", "Follicular Lymphoma", "Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" }, { "name": "Lenalidomide", "type": "COMBINATION_PRODUCT" }, { "name": "Rituximab", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 599, "start_date": "2020-06-11", "completion_date": "2029-03-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 57, "location_summary": "Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Cerritos", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04224493" }, { "nct_id": "NCT07187921", "title": "Evaluation of a Finger Prick Collection Method for Measuring Alzheimer's Disease Blood Biomarkers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Alzheimer Disease" ], "interventions": [], "intervention_types": [], "sponsor": "Banner Health", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 49, "start_date": "2025-09-29", "completion_date": "2025-11-12", "has_results": false, "last_update_posted_date": "2025-12-09", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT07187921" }, { "nct_id": "NCT04197687", "title": "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Adenocarcinoma", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Multi-epitope HER2 Peptide Vaccine TPIV100", "type": "BIOLOGICAL" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 480, "start_date": "2020-02-20", "completion_date": "2025-01-15", "has_results": false, "last_update_posted_date": "2023-12-18", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 30, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Yuma, Arizona + 26 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04197687" }, { "nct_id": "NCT00016107", "title": "Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Hormone-resistant Prostate Cancer", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "estramustine phosphate sodium", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 72, "start_date": "2001-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016107" }, { "nct_id": "NCT07805343", "title": "Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rejection Acute Renal", "Rejection Chronic Renal", "Transplantation", "Kidney Rejection Transplant" ], "interventions": [ { "name": "Donor-derived cell-free DNA", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Paris Translational Research Center for Organ Transplantation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5000, "start_date": "2024-06-15", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 14, "location_summary": "Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07805343" }, { "nct_id": "NCT07622589", "title": "NeuroFinance Human Stress Trial During Financial and Informational Volatility", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Psychological Stress", "Anxiety", "Emotional Stress", "Autonomic Nervous System Dysfunction", "Sleep Disturbance", "Insomnia", "Behavioral Health", "Cognitive Fatigue", "Occupational Stress", "Financial Stress", "Burnout Syndrome", "Heart Rate Variability", "Neurobehavioral Manifestations" ], "interventions": [ { "name": "Wearable Physiologic Monitoring Platform", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Truway Health, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2500, "start_date": "2026-07-15", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07622589" }, { "nct_id": "NCT00500617", "title": "Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Coronary Artery Disease", "Angina Pectoris", "Chest Pain", "Cardiovascular Diseases", "Coronary Heart Disease", "CAD", "CVD", "CHD" ], "interventions": [ { "name": "Corus CAD (ASGES)", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "CardioDx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "21 Years to 99 Years" }, "enrollment_count": 4350, "start_date": "2007-07", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2019-01-31", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 10, "location_summary": "Anchorage, Alaska • Beverly Hills, California • La Jolla, California + 7 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00500617" }, { "nct_id": "NCT00096590", "title": "Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Thromboembolism", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "coagulation study", "type": "OTHER" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "physiologic testing", "type": "OTHER" }, { "name": "study of high risk factors", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2004-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-05-12", "last_synced_at": "2026-10-15T12:11:36.224Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096590" } ] }